Lyell Immunopharma, Inc. (LYEL) stock
Close on Nov 12, 2026Market cap $383.26MP/E –Yield –
Lyell Immunopharma, Inc. saw revenue fall 63.4% to $15.00K over the twelve months to Sep 30, 2026. Free cash flow was -$139.97M. At the latest close the market valued the company at $383.26M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $383.26M
- P/E ratio
- –
- Price to sales
- 25550.70
- Price to book
- 1.99
- Dividend yield
- –
- Free cash flow yield
- -36.52%
Fundamentals
- Revenue
- $15.00K
- Net income
- -$255.16M
- EPS, diluted
- -$11.74
- Free cash flow
- -$139.97M
- Book value per share
- $7.89
- Diluted shares
- 24M
Trading
- Next earnings
- Mar 11, 2027 (estimated, after the close)
- Previous close
- $16.86
- Open
- $16.70
- Day's range
- $15.50 – $16.86
- Volume
- 130,957
- Average volume (20 days)
- 231,377
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 1.42
- 52-week range
- $7.20 – $45.00
- RSI (14 days)
- 69.3
- Volatility (1 year)
- 91.5%
- Relative volume
- 0.77×
- WACC
- 12.0%
On 1 of our idea list: Insiders buying the dip
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | LYEL | S&P 500 | Difference | LYEL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +89.1% | -2.7% | +91.8 pts | ||
| 3 months | +10.4% | -1.7% | +12.1 pts | ||
| Year to date | -49.2% | +11.9% | −61.1 pts | ||
| 1 year | -11.3% | +12.0% | −23.3 pts | ||
| 3 years | -52.7% | +78.2% | −130.9 pts | -22.1% | +21.2% |
| 5 years | -93.1% | +73.2% | −166.4 pts | -41.5% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Lyell Immunopharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- Results
- Results
- Results
About Lyell Immunopharma
Pharmaceutical Preparations
Lyell is a clinical-stage biotechnology company that develops autologous chimeric antigen receptor T-cell therapies for cancer patients. The company focuses on hematologic malignancies and solid tumors, modifying patient immune cells to target cancerous tissues. Its lead product candidate is rondecabtagene autoleucel, a dual-targeting CD19 and CD20 cell therapy in clinical trials for large B-cell lymphoma. The company also develops LYL273, a cell therapy candidate targeting guanylyl cyclase C for patients with advanced metastatic colorectal cancer. Lyell's therapies target cancer patients with relapsed, refractory, or advanced malignancies.
Company profile, executives and historyLyell Immunopharma stock: common questions
What is Lyell Immunopharma's stock price?
LYEL closed at $15.64 on Nov 12, 2026, down 7.24% on the day. Over the past 52 weeks it traded between $7.20 and $45.00.
What is Lyell Immunopharma's market cap?
Lyell Immunopharma was worth $383.26M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is LYEL's P/E ratio?
Lyell Immunopharma lost money over the twelve months to Sep 30, 2026 (diluted EPS -$11.74), so it has no meaningful P/E ratio.
How much revenue does Lyell Immunopharma make?
Lyell Immunopharma reported revenue of $15.00K for the twelve months to Sep 30, 2026, down 63.4% from a year earlier.
Does Lyell Immunopharma pay a dividend?
No. Lyell Immunopharma has not paid a cash dividend over the last twelve months.
When does Lyell Immunopharma report earnings next?
Lyell Immunopharma is expected to report Q4 FY2026 results on Mar 11, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has LYEL stock performed over the past year?
Including dividends, LYEL returned -11.3% over the past year, against +12.0% for the S&P 500.
How many LYEL shares are sold short?
1M shares were sold short at the latest FINRA report, 10.45% of the float, or 10.4 days of average trading volume.
Who are Lyell Immunopharma's competitors?
Companies most similar to Lyell Immunopharma by business, industry and size include ALLO, GNLX, KZIA, SNTI, NTHI.
See a number that looks wrong?